Evidence
Mol Cell Proteomics. 2024 Jan 19:100721. doi: 10.1016/j.mcpro.2024.100721. Online ahead of print.
ABSTRACT
Alzheimer’s disease (AD) is characterised by several neuropathological changes, mainly extracellular amyloid aggregates (plaques), intraneuronal inclusions of phosphorylated tau (tangles), as well as neuronal and synaptic degeneration, accompanied by tissue reactions to these processes (astrocytosis and microglial activation) that precede neuronal network disturbances in the symptomatic phase of the disease. A number of biomarkers for these brain tissue changes have been developed, mainly using immunoassays. In this review, we discuss how targeted mass spectrometry (TMS) can be used to validate and further characterize classes of biomarkers reflecting different AD pathologies, such as tau- and amyloid-beta pathologies, synaptic dysfunction, lysosomal dysregulation, and axonal damage, and the prospect of using TMS to measure these proteins in clinical research and diagnosis. TMS advantages and disadvantages in relation to immunoassays are discussed, and complementary aspects of the technologies are discussed.
PMID:38246483 | DOI:10.1016/j.mcpro.2024.100721
Estimated reading time: 3 minute(s)
Latest: Psychiatryai.com #RAISR4D Evidence
Cool Evidence: Engaging Young People and Students in Real-World Evidence
Real-Time Evidence Search [Psychiatry]
AI Research
Alzheimer’s disease biomarker analysis using targeted mass spectrometry
🌐 90 Days
AI Virtual Reality Related Evidence Matrix
- An interim exploratory proteomics biomarker analysis of a phase 2 clinical trial to assess the impact of CT1812 in Alzheimer's disease
- Associations of amyloid-beta oligomers and plaques with neuropathology in the App (NL-G-F) mouse
- Associations of amyloid-beta oligomers and plaques with neuropathology in the App (NL-G-F) mouse
- Distinct transcriptional alterations distinguish Lewy body disease from Alzheimer's disease
- Distinct transcriptional alterations distinguish Lewy body disease from Alzheimer's disease
- Considerations for biomarker strategies in clinical trials investigating tau-targeting therapeutics for Alzheimer's disease
- Integrative proteomics identifies a conserved Aβ amyloid responsome, novel plaque proteins, and pathology modifiers in Alzheimer's disease
- Tau protein profiling in tauopathies: a human brain study
- Microglia-astrocyte crosstalk in the amyloid plaque niche of an Alzheimer's disease mouse model, as revealed by spatial transcriptomics
- Amyloid-β peptide signature associated with cerebral amyloid angiopathy in familial Alzheimer's disease with APPdup and Down syndrome
- Co-registration of MALDI-MSI and histology demonstrates gangliosides co-localize with amyloid beta plaques in Alzheimer's disease
- Co-registration of MALDI-MSI and histology demonstrates gangliosides co-localize with amyloid beta plaques in Alzheimer's disease
- Liver as a new target organ in Alzheimer's disease: insight from cholesterol metabolism and its role in amyloid-beta clearance
- In situ seeding assay: A novel technique for direct tissue localization of bioactive tau
- Towards cascading genetic risk in Alzheimer's disease
- Blood Pressure Variability and Plasma Biomarkers of Neuronal Injury and Alzheimer's Disease: A Clinic-Based Study of Patients with Diseases Along the Heart-Brain Axis
- Blood biomarkers open a window to brain pathophysiology in Alzheimer's disease
- Network proteomics of the Lewy body dementia brain reveals presynaptic signatures distinct from Alzheimer's disease
- Enhanced microglial dynamics and a paucity of tau seeding in the amyloid plaque microenvironment contribute to cognitive resilience in Alzheimer's disease
- Evaluation of cerebrospinal fluid (CSF) and interstitial fluid (ISF) mouse proteomes for the validation and description of Alzheimer's disease biomarkers
- Role of PIM Kinase Inhibitor in the Treatment of Alzheimer's Disease
- Cerebrospinal fluid biomarkers and cognitive trajectories in patients with Alzheimer's disease and a history of traumatic brain injury
- Clinical and diagnostic implications of Alzheimer's disease copathology in Lewy body disease
- Factors Affecting Resilience and Prevention of Alzheimer's Disease and Related Dementias
- P2Y1 receptor in Alzheimer's disease
- Brain vasculature accumulates tau and is spatially related to tau tangle pathology in Alzheimer's disease
- Characterization of reduced astrocyte creatine kinase levels in Alzheimer's disease
- Effects of time of the day at sampling on CSF and plasma levels of Alzheimer' disease biomarkers
- Effects of time of the day at sampling on CSF and plasma levels of Alzheimer' disease biomarkers
- Revised criteria for diagnosis and staging of Alzheimer's disease: Alzheimer's Association Workgroup
- Modern neurophysiological techniques indexing normal or abnormal brain aging
- Ketone body metabolism and the NLRP3 inflammasome in Alzheimer's disease
- Modeling late-onset Alzheimer's disease neuropathology via direct neuronal reprogramming
- Improving Cognition Without Clearing Amyloid: Effects of Tau and Ultrasound Neuromodulation
- Alzheimer's disease and sleep disorders: a bidirectional relationship
- Cryo-EM structures of cotton wool plaques' amyloid β and of tau filaments in dominantly inherited Alzheimer disease
- Single-extracellular vesicle (EV) analyses validate the use of L1 Cell Adhesion Molecule (L1CAM) as a reliable biomarker of neuron-derived EVs
- Evidence for a novel neuronal mechanism driving Alzheimer's disease, upstream of amyloid
- Hypoglycemia and Alzheimer Disease Risk: The Possible Role of Dasiglucagon
- Evaluation of altered cell-cell communication between glia and neurons in the hippocampus of 3xTg-AD mice at two time points
- Regulation of cell distancing in peri-plaque glial nets by Plexin-B1 affects glial activation and amyloid compaction in Alzheimer's disease
- Central nervous system-derived extracellular vesicles: the next generation of neural circulating biomarkers?
- Activation of the Neuronal Cell Cycle in Brains in Amnestic Mild Cognitive Impairment: Early Involvement in the Progression of Alzheimer's Disease
- Chronic kidney disease leads to microglial potassium efflux and inflammasome activation in the brain
- Post-GWAS multiomic functional investigation of the TNIP1 locus in Alzheimer's disease highlights a potential role for GPX3
- Involvement of the choroid plexus in Alzheimer's disease pathophysiology: findings from mouse and human proteomic studies
- Involvement of the choroid plexus in Alzheimer's disease pathophysiology: findings from mouse and human proteomic studies
- Tobacco cigarette smoking induces cerebrovascular dysfunction followed by oxidative neuronal injury with the onset of cognitive impairment
- 1-Deoxynojirimycin attenuates pathological markers of Alzheimer's disease in the in vitro model of neuronal insulin resistance
- Amino-terminally elongated Aβ peptides are generated by the secreted metalloprotease ADAMTS4 and deposit in a subset of Alzheimer's disease brains
- Changes in Alzheimer Disease Blood Biomarkers and Associations With Incident All-Cause Dementia
- Inflammasomes in chronic liver disease: hepatic injury, fibrosis progression and systemic inflammation
- Inflammasomes in chronic liver disease: hepatic injury, fibrosis progression and systemic inflammation
- Tau pathology mediate the plasma biomarkers and cognitive function in patients with mild cognitive impairment
- Altering plasma lipids and liver enzyme activities via hippocampal injections of hen Lysozyme amyloid aggregates in an Alzheimer's disease mouse model: Insights into the therapeutic role of Bis (Indolyl) phenylmethane
- Search for unknown neural link between the masticatory and cognitive brain systems to clarify the involvement of its impairment in the pathogenesis of Alzheimer's disease
- Application of omics in the diagnosis, prognosis, and treatment of acute myeloid leukemia
- A cross-sectional study of α-synuclein seed amplification assay in Alzheimer's disease neuroimaging initiative: Prevalence and associations with Alzheimer's disease biomarkers and cognitive function
- Cannabidiol protects mouse hippocampal neurons from neurotoxicity induced by amyloid β-peptide25-35
- Neuroimmune Dysfunction in Alzheimer's Disease and Other Forms of Dementia
- Astrocyte tau deposition in progressive supranuclear palsy is associated with dysregulation of MAPT transcription
- Differences in the cerebral amyloid angiopathy proteome in Alzheimer's disease and mild cognitive impairment
- Assessing cognitive impairment and disability in older adults through the lens of whole brain white matter patterns
- Assessing cognitive impairment and disability in older adults through the lens of whole brain white matter patterns
Evidence Blueprint
Alzheimer’s disease biomarker analysis using targeted mass spectrometry
☊ AI-Driven Related Evidence Nodes
(recent articles with at least 5 words in title)
More Evidence
Alzheimer’s disease biomarker analysis using targeted mass spectrometry
🌐 365 Days
AI Virtual Reality Related Evidence Matrix
- Comparison of immunoassay- with mass spectrometry-derived p-tau quantification for the detection of Alzheimer's disease pathology
- An interim exploratory proteomics biomarker analysis of a phase 2 clinical trial to assess the impact of CT1812 in Alzheimer's disease
- Associations of amyloid-beta oligomers and plaques with neuropathology in the App (NL-G-F) mouse
- Associations of amyloid-beta oligomers and plaques with neuropathology in the App (NL-G-F) mouse
- Distinct transcriptional alterations distinguish Lewy body disease from Alzheimer's disease
- Distinct transcriptional alterations distinguish Lewy body disease from Alzheimer's disease
- Next-generation proteomics technologies in Alzheimer's disease: from clinical research to routine diagnostics
- Amyloid-β and Phosphorylated Tau are the Key Biomarkers and Predictors of Alzheimer's Disease
- Considerations for biomarker strategies in clinical trials investigating tau-targeting therapeutics for Alzheimer's disease
- Cerebrospinal fluid biomarker panel for synaptic dysfunction in a broad spectrum of neurodegenerative diseases
- Phosphorylation-state dependent intraneuronal sorting of Aβ differentially impairs autophagy and the endo-lysosomal system
- Genomic stress and impaired DNA repair in Alzheimer disease
- Targeted examination of amyloid beta and tau protein accumulation via positron emission tomography for the differential diagnosis of Alzheimer's disease based on the A/T(N) research framework
- Alzheimer Disease Biomarkers: Moving from CSF to Plasma for Reliable Detection of Amyloid and tau Pathology
- Integrative proteomics identifies a conserved Aβ amyloid responsome, novel plaque proteins, and pathology modifiers in Alzheimer's disease
- Tau protein profiling in tauopathies: a human brain study
- Microglia-astrocyte crosstalk in the amyloid plaque niche of an Alzheimer's disease mouse model, as revealed by spatial transcriptomics
- Amyloid-β peptide signature associated with cerebral amyloid angiopathy in familial Alzheimer's disease with APPdup and Down syndrome
- Serum GFAP levels correlate with astrocyte reactivity, post-mortem brain atrophy and neurofibrillary tangles
- Co-registration of MALDI-MSI and histology demonstrates gangliosides co-localize with amyloid beta plaques in Alzheimer's disease
- Co-registration of MALDI-MSI and histology demonstrates gangliosides co-localize with amyloid beta plaques in Alzheimer's disease
- Liver as a new target organ in Alzheimer's disease: insight from cholesterol metabolism and its role in amyloid-beta clearance
- Spatial Neurolipidomics at the Single Amyloid-β Plaque Level in Postmortem Human Alzheimer's Disease Brain
- In situ seeding assay: A novel technique for direct tissue localization of bioactive tau
- Integration of Microfluidic Devices with Microelectrode Arrays to Functionally Assay Amyloid-β-Induced Synaptotoxicity
- Multiple system atrophy with amyloid-b-predominant Alzheimer's disease neuropathologic change
- Navigating the Dementia Landscape: Biomarkers and Emerging Therapies
- Towards cascading genetic risk in Alzheimer's disease
- Personalized whole-brain neural mass models reveal combined Ab and tau hyperexcitable influences in Alzheimer's disease
- p-tau Ser356 is associated with Alzheimer's disease pathology and is lowered in brain slice cultures using the NUAK inhibitor WZ4003
- CSF 14-3-3β is associated with progressive cognitive decline in Alzheimer's disease
- Blood Pressure Variability and Plasma Biomarkers of Neuronal Injury and Alzheimer's Disease: A Clinic-Based Study of Patients with Diseases Along the Heart-Brain Axis
- Plasma brain-derived tau is an amyloid-associated neurodegeneration biomarker in Alzheimer's disease
- Reactive astrocytes secrete the chaperone HSPB1 to mediate neuroprotection
- CSF p-tau205: a biomarker of tau pathology in Alzheimer's disease
- Induced pluripotent stem cell models as a tool to investigate and test fluid biomarkers in Alzheimer's disease and frontotemporal dementia
- CSF metabolites associated with biomarkers of Alzheimer's disease pathology
- Blood biomarkers open a window to brain pathophysiology in Alzheimer's disease
- Network proteomics of the Lewy body dementia brain reveals presynaptic signatures distinct from Alzheimer's disease
- Remodelling of the cardiac extracellular matrix proteome during chronological and pathological ageing
- Ischemia-Reperfusion Programming of Alzheimer's Disease-Related Genes-A New Perspective on Brain Neurodegeneration after Cardiac Arrest
- Neuropathology of Alzheimer's Disease
- Enhanced microglial dynamics and a paucity of tau seeding in the amyloid plaque microenvironment contribute to cognitive resilience in Alzheimer's disease
- Proteomics Impact on Cell Biology to Resolve Cell Structure and Function
- Validating blood tests as a possible routine diagnostic assay of Alzheimer's disease
- Evaluation of cerebrospinal fluid (CSF) and interstitial fluid (ISF) mouse proteomes for the validation and description of Alzheimer's disease biomarkers
- Spatial transcriptomic patterns underlying amyloid-β and tau pathology are associated with cognitive dysfunction in Alzheimer's disease
- Passive tau-based immunotherapy for tauopathies
- Fe65-engineered neuronal exosomes encapsulating corynoxine-B ameliorate cognition and pathology of Alzheimer's disease
- Role of PIM Kinase Inhibitor in the Treatment of Alzheimer's Disease
- Cerebrospinal fluid biomarkers and cognitive trajectories in patients with Alzheimer's disease and a history of traumatic brain injury
- Blood-Based Biomarkers for Early Alzheimer's Disease Diagnosis in Real-World Settings
- Proteomic analysis of P. gingivalis-Lipopolysaccharide induced neuroinflammation in SH-SY5Y and HMC3 cells
- Biomarkers associated with the pathogenesis of Alzheimer's disease
- Human iPSC-derived retinal organoids develop robust Alzheimer's disease neuropathology
- Evaluation of SP3 for antibody-free quantification of tau in CSF mimic and brain by mass spectrometry
- Neuropsychiatric Symptoms and Microglial Activation in Patients with Alzheimer Disease
- Clinical and diagnostic implications of Alzheimer's disease copathology in Lewy body disease
- Plasma p-tau212: antemortem diagnostic performance and prediction of autopsy verification of Alzheimer's disease neuropathology
- Large-scale proteomics analysis of five brain regions from Parkinson's disease patients with a GBA1 mutation
- Large-scale proteomics analysis of five brain regions from Parkinson's disease patients with a GBA1 mutation
- The Biochemistry Behind Cognitive Decline: Biomarkers of Alzheimer's Disease
- Resiliency to Alzheimer's disease neuropathology can be distinguished from dementia using cortical astrogliosis imaging
- Factors Affecting Resilience and Prevention of Alzheimer's Disease and Related Dementias